A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
18 - 74 Years, Male and Female
90301900HNC1001 (primary)
NCI-2025-09717
2025
2025-522914-22-00
90301900HNC1001
Summary
This global, open-label, single arm, phase 1b study aims to learn more about whether a
treatment called JNJ-90301900 is safe and effective when injected directly into tumors,
along with standard chemotherapy and radiation therapy, for participants with head and
neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer
of the mouth & throat).
Eligibility
- Pathologically (histologically or cytologically) proven diagnosis of HNSCC of the oral cavity, oropharynx (p16 negative), hypopharynx, or supraglottic larynx
- Stage III, IVA or IVB according to the 8th Edition of the American Joint Committee on Cancer (AJCC) guidelines
- A candidate for definitive concurrent chemoradiation therapy treatment as determined by investigator and per local guidelines
- Participants must have at least 1 target lesion (primary tumor or involved lymph node) per RECIST v.1.1
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.